An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

254 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-07

Study Completion Date

2025-11-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the pharmacokinetic (PK) exposures of a single subcutaneous (SC) dose of tozorakimab administered using AI or APFS in healthy participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of [14C]-LY4065967 in Healthy Participants

NCT07039045

Healthy

COMPLETED PHASE1

Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants

NCT06106074

Multiple Sclerosis

COMPLETED PHASE1

OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study

NCT06270771

MDS Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms +1 more

RECRUITING

To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects

NCT05982106

Myelofibrosis

COMPLETED PHASE1

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

NCT06245941

Myelofibrosis

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multiple center, randomized, open-label, parallel group, Phase 1 study.

Participants will be randomized 1:1:1:1:1:1 to one of the 6 combinations of the devices (APFS or AI devices) and one of three injection sites (abdomen, thigh, or upper arm.).

The study includes:

* A screening period of up to 28 days.
* A treatment period (up to 9 days).
* A follow-up period till 85 days.
* A final follow-up visit on Day 113 (Week 16).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A: Tozorakimab (Test)

Participants will receive a single SC dose of tozorakimab via AI device.

Group Type EXPERIMENTAL

Tozorakimab

Intervention Type DRUG

Tozorakimab will be administered as a single SC dose using an AI or APFS device on Day 1.

Autoinjector (AI) Device

Intervention Type DEVICE

AI device will be used to administer single SC dose of tozorakimab on Day 1.

Treatment B: Tozorakimab (Reference)

Participants will receive a single SC dose of tozorakimab via APFS device with the same container closure as the AI.

Group Type ACTIVE_COMPARATOR

Tozorakimab

Intervention Type DRUG

Tozorakimab will be administered as a single SC dose using an AI or APFS device on Day 1.

Accessorised Prefilled Syringe (APFS) Device

Intervention Type DEVICE

APFS device will be used to administer single SC dose of tozorakimab on Day 1.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tozorakimab

Tozorakimab will be administered as a single SC dose using an AI or APFS device on Day 1.

Intervention Type DRUG

Autoinjector (AI) Device

AI device will be used to administer single SC dose of tozorakimab on Day 1.

Intervention Type DEVICE

Accessorised Prefilled Syringe (APFS) Device

APFS device will be used to administer single SC dose of tozorakimab on Day 1.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MEDI3506

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults with suitable veins for cannulation or repeated venipuncture.
* All females must have a negative pregnancy test at the screening visit and on admission.
* Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception, in order to avoid pregnancy from the time of administration of study intervention until 16 weeks after administration of the study intervention (Day 113).
* Females of non-childbearing potential must be confirmed at the screening visit.
* Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods from the time of administration of the study intervention until 16 weeks after administration of the study intervention (Day 113).
* Have a body mass index (BMI) between 19 and 30 kg/m2 inclusive and weigh at least 55 kg and no more than 100 kg inclusive at screening and Day -1.
* Intact normal skin without potentially obscuring tattoos, scars, etc., at the injection site.

Exclusion Criteria

* History of any clinically significant disease or disorder which may either put the participant at risk because of participation in the study or influence the results of the study or the participant's ability to participate in the study.
* Any clinically important medical/surgical procedure or trauma within 8 weeks of the screening visit, or any planned inpatient hospitalization during the study period.
* Malignancy, current or within the past 5 years, suspected malignancy or undefined neoplasms.
* Any abnormal laboratory values and vital signs.
* History of known immunodeficiency disorder, including a positive test for human immunodeficiency virus (HIV)-1 or HIV-2.
* History or treatment for hepatitis B or hepatitis C or any positive test result on screening for hepatitis B surface antigen (HBsAg), anti-hepatitis B core (HBc) antibodies, or anti-hepatitis C antibodies.
* Evidence of currently active tuberculosis (TB) disease or use of any TB drug treatment in the past 12 months or latent TB infection.
* Any clinically significant abnormalities on 12lead electrocardiogram (ECG) at the screening visit and/or admission (Day -1) to the Clinical Unit.
* History of or ongoing severe clinically important allergy/hypersensitivity, or history of hypersensitivity to monoclonal or polyclonal antibodies. History of allergy or reaction to any formulation components of the investigational medicinal product (IMP).
* Receipt of live attenuated vaccines within 30 days prior to randomization and receipt of COVID-19 or inactivated vaccines within 14 days prior to randomization.
* Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months or 5 half-lives of time of dosing in this study, whichever is longer.
* Receipt of any investigational biologic within 4 months or 5 half-lives prior to the date of dosing in this study, whichever is longer.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes